Statins and proteinuria
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The proteinuria associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors is composed of primarily low-molecular weight proteins that disappear rapidly following discontinuation of the statin agent. More importantly, no evidence exists of nephrotoxicity or reduced renal function observed with the approved clinical dosages of any available statins. Recent clinical studies have suggested actual improvement in renal function demonstrated by decreases in creatinine concentrations and improvement in estimated glomerular filtration rates with both short-term and long-term administration of these agents. The progressive fibrosis and renal scarring of chronic kidney disease appears to be the end result of increased protein traffic in the proximal renal tubule. Early animal and recent clinical studies have suggested that treatment with statin agents in established chronic kidney disease can, in fact, provide renoprotection over and above that observed with aggressive blood pressure control and the use of angiotensin II antagonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The proteinuria induced by statins is of tubular origin and is supposed to be due to reduced tubular reabsorption and not to glomerular dysfunction. 229”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [229]
In the citing paper
“The proteinuria induced by statins is of tubular origin and is supposed to be due to reduced tubular reabsorption and not to glomerular dysfunction.229”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [229]
Citations
Cites
DAOUD, G. (1965) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1965.02090030355030 · Cited by 1,171
Department of Health and Human Services
(2002) · Handbook of Research Design & Social Measurement · doi:10.4135/9781412984386.n104 · Cited by 1,032
Regression of Microalbuminuria in Type 1 Diabetes
Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021835 · Cited by 801
Effect of lipid reduction on the progression of renal disease: A meta-analysis
Fried, L. F., Orchard, T. J., & Kasiske, B. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00487.x · Cited by 672
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12475-0 · Cited by 492
Pathways to nephron loss starting from glomerular diseases—Insights from animal models
Kriz, W., & Lehir, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67097.x · Cited by 468
Megalin Knockout Mice as an Animal Model of Low Molecular Weight Proteinuria
Leheste, J.-R., Rolinski, B., Vorum, H., Hilpert, J., Nykjaer, A., Jacobsen, C., Aucouturier, P., Moskaug, J. Ø., Otto, A., Christensen, E. I., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65238-8 · Cited by 443
Zoja, C., Donadelli, R., Colleoni, S., Figliuzzi, M., Bonazzola, S., Morigi, M., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00905.x · Cited by 419
Research works printed but not linked: 1
- Maack T: Renal filtration, transport and metabolism of protein. In The Kidney, edn 3. Edited by Seldin DW, Giebish G. Philadelphia: Lippincott, Williams & Wilkins; 2000: 2235–2267.
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Residual microvascular risk in diabetes: unmet needs and future directions
Fioretto, P., Dodson, P. M., Ziegler, D., & Rosenson, R. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.213 · Cited by 115
Zhang, Z., Wu, P., Zhang, J., Wang, S., & Zhang, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.005 · Cited by 66
Metadata
- Authors
- Vidt, D. G.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Vidt, Donald G.
- Venue
- Current Atherosclerosis Reports
- Published
- 2005-09
- Volume
- 7
- Issue
- 5
- Pages
- 351-357
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W2084325514
- Cited by
- 18
- References
- 50
- Citations by year
- 2025: 1 · 2022: 1 · 2020: 1 · 2016: 3 · 2014: 1 · 2013: 1 · 2012: 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Atherosclerosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- statins, proteinuria, nephrotoxicity, renal function, glomerular filtration rate, chronic kidney disease, renal fibrosis, renal protection, low molecular weight proteins, creatinine
- MeSH terms
- Animals, Humans, Hydroxymethylglutaryl CoA Reductases, Kidney Tubules, Proteinuria, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins and proteinuria. https://app.cochat.ai/papers/10.1007/s11883-005-0046-9
- The paper
- Vidt, D. G. (2005). Statins and proteinuria. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-005-0046-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.